메뉴 건너뛰기
New England Journal of Medicine
Volumn 375, Issue 4, 2016, Pages 380-382
Cardiac and renovascular complications in type 2 diabetes - Is there hope?
Author keywords

[No Author keywords available]
Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; CANAGLIFLOZIN; DAPAGLIFLOZIN; DULAGLUTIDE; EMPAGLIFLOZIN; EXENDIN 4; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; PIOGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;
EID: 84979884860     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1607413     Document Type: Review
Times cited : (34)
References (10)
  • 1
    • 38149142887 scopus 로고    scopus 로고
    • Geneva: World Health Organization, June
    • Diabetes: fact sheet. Geneva: World Health Organization, June 2016 (http://www.who.int/mediacentre/factsheets/fs312/en/).
    • (2016) Diabetes: Fact Sheet
  • 2
    • 84883745765 scopus 로고    scopus 로고
    • Alogliptin after acute coronary syndrome in patients with type 2 diabetes
    • White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35.
    • (2013) N Engl J Med , vol.369 , pp. 1327-1335
    • White, W.B.1    Cannon, C.P.2    Heller, S.R.3
  • 3
    • 84883765959 scopus 로고    scopus 로고
    • Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes melli-tus
    • Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes melli-tus. N Engl J Med 2013; 369: 1317-26.
    • (2013) N Engl J Med , vol.369 , pp. 1317-1326
    • Scirica, B.M.1    Bhatt, D.L.2    Braunwald, E.3
  • 4
    • 84937053742 scopus 로고    scopus 로고
    • Effect of sita-gliptin on cardiovascular outcomes in type 2 diabetes
    • Green JB, Bethel MA, Armstrong PW, et al. Effect of sita-gliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-42.
    • (2015) N Engl J Med , vol.373 , pp. 232-242
    • Green, J.B.1    Bethel, M.A.2    Armstrong, P.W.3
  • 5
    • 84948740668 scopus 로고    scopus 로고
    • Lixisenatide in patients with type 2 diabetes and acute coronary syndrome
    • Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-57.
    • (2015) N Engl J Med , vol.373 , pp. 2247-2257
    • Pfeffer, M.A.1    Claggett, B.2    Diaz, R.3
  • 6
    • 84978839381 scopus 로고    scopus 로고
    • Liraglutide and cardiovascular outcomes in type 2 diabetes
    • Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-22.
    • (2016) N Engl J Med , vol.375 , pp. 311-322
    • Marso, S.P.1    Daniels, G.H.2    Brown-Frandsen, K.3
  • 7
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
    • (2015) N Engl J Med , vol.373 , pp. 2117-2128
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3
  • 8
    • 26244453309 scopus 로고    scopus 로고
    • Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial
    • Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
    • (2005) Lancet , vol.366 , pp. 1279-1289
    • Dormandy, J.A.1    Charbonnel, B.2    Eckland, D.J.3
  • 9
    • 84964703072 scopus 로고    scopus 로고
    • Evaluating the cardiovascular safety of new medications for type 2 diabetes: Time to reassess?
    • Smith RJ, Goldfine AB, Hiatt WR. Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess? Diabetes Care 2016; 39: 738-42.
    • (2016) Diabetes Care , vol.39 , pp. 738-742
    • Smith, R.J.1    Goldfine, A.B.2    Hiatt, W.R.3
  • 10
    • 84979895487 scopus 로고    scopus 로고
    • Empagliflozin and progression of kidney disease in type 2 diabetes
    • Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34.
    • (2016) N Engl J Med , vol.375 , pp. 323-334
    • Wanner, C.1    Inzucchi, S.E.2    Lachin, J.M.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.